---
title: "Fosun Pharmaceutical Gets US FDA Approval for HLX99 Clinical Trials"
date: "2025-02-11 11:07:04"
summary: "Shanghai Fosun Pharmaceutical received approval from the US Food and Drug Administration to conduct phase one clinical trials for HLX99. The drug is used for the treatment of amyotrophic lateral sclerosis, according to a Monday filing with the Shanghai bourse. Shares of the pharmaceutical company were down 1% in recent..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Shanghai Fosun Pharmaceutical received approval from the US Food and Drug Administration to conduct phase one clinical trials for HLX99.

The drug is used for the treatment of amyotrophic lateral sclerosis, according to a Monday filing with the Shanghai bourse.

Shares of the pharmaceutical company were down 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465962:0/)
